文献速递糖尿病肥胖与代谢综合征

胰高血糖素样肽-1受体激动剂与糖尿病合并肥胖个体中自杀意念及自伤的相关性:一项倾向加权、基于人群的队列研究

Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
PubMed 文献 · Diabetologia · 2024-08-06

采用新使用者、活性对照设计与逆概率治疗加权Cox回归,未发现GLP-1RA增加自杀意念及自伤(SIS)发生率的证据,但事件罕见、效应估计不确定性宽,作者呼吁谨慎解读。

要点

  • 主要符合方案分析中,GLP-1RA与SGLT-2i相比SIS的HR为1.04(95%CI 0.35,3.14)。
  • 意向性治疗分析HR为1.36(95%CI 0.51,3.61),均未达统计学显著。
  • 作者指出SIS事件罕见且效应不确定性宽,效应可能高达三倍,需谨慎解读。

核心结论

  • 研究结果不支持2型糖尿病合并肥胖个体使用GLP-1RA会增加SIS风险;但SIS事件罕见且效应量不确定性宽(虽为零效应,风险仍可能高达三倍),作者呼吁谨慎解读结果。
  • 作者呼吁进一步研究,包括监管机构的最终评估,以排除GLP-1RA与自杀倾向之间的因果关系。

研究设计与样本

  • 纳入2015至2021年因2型糖尿病合并肥胖而新启用GLP-1RA或SGLT-2i治疗的全部成人。
  • 采用新使用者、活性对照设计,并以倾向评分为基础进行逆概率治疗加权(IPTW)的多变量Cox回归建模。
  • 共纳入启用GLP-1RA者3040例与启用SGLT-2i者11627例。
  • 研究进行了多项分层与敏感性分析。

主要发现

  • 与SGLT-2i组相比,GLP-1RA组更年轻(55岁 vs 60岁,p<0.001)。
  • GLP-1RA组较SGLT-2i组焦虑更多(49.4% vs 41.5%,p<0.001)、睡眠障碍更多(43.2% vs 34.1%,p<0.001)、抑郁更多(24.4% vs 19.0%,p<0.001)。
  • GLP-1RA组BMI≥40者比例高于SGLT-2i组(35.1% vs 15.1%,p<0.001)。
  • 倾向评分加权后,所有协变量的组间标准化均数差均<0.1,显示基线调整后两组平衡良好。
  • 主要符合方案分析未发现GLP-1RA增加SIS发生率的证据(HR 1.04;95%CI 0.35,3.14);意向性治疗分析HR为1.36(95%CI 0.51,3.61);排除无BMI信息者并用插补处理BMI缺失值后,相应HR分别为0.89(95%CI 0.26,3.14)与1.29(95%CI 0.42,3.92);分层分析各亚组间无差异。

关键数值与推荐

  • 主要符合方案分析:GLP-1RA vs SGLT-2i的SIS发生HR 1.04(95%CI 0.35,3.14)。
  • 意向性治疗分析:HR 1.36(95%CI 0.51,3.61)。
  • 排除无BMI信息者后HR 0.89(95%CI 0.26,3.14);用插补处理BMI缺失值后HR 1.29(95%CI 0.42,3.92)。
  • 倾向评分加权后所有协变量标准化均数差<0.1。

临床怎么用

  • 原文未据此给出推荐;作者认为结果不支持GLP-1RA增加SIS风险,但强调事件罕见与效应不确定性宽,呼吁谨慎解读并进一步研究。

局限性

  • SIS事件罕见。
  • 效应量不确定性宽,虽为零效应,风险仍可能高达三倍。
  • 作者呼吁进一步研究,包括监管机构的最终评估,以排除GLP-1RA与自杀倾向的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) in individuals taking liraglutide and semaglutide. We aimed to assess the risk of SIS in new users of GLP-1RA when compared with sodium-glucose cotransporter 2 inhibitors (SGLT-2i) users, prescribed to treat type 2 diabetes in individuals with obesity. METHODS: This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021. To estimate the comparative effect of GLP-1RA on the risk of SIS, we employed a new user, active comparator design and we carried out multivariable Cox regression modelling with inverse probability of treatment weighting (IPTW) based on propensity scores. We performed several stratified and sensitivity analyses. RESULTS: We included 3040 patients initiating treatment with GLP-1RA and 11,627 with SGLT-2i. When compared with patients treated with SGLT-2i, those in the GLP-1RA group were younger (55 vs 60 years old, p<0.001), had more anxiety (49.4% vs 41.5%, p<0.001), sleep disorders (43.2% vs 34.1%, p<0.001) and depression (24.4% vs 19.0%, p<0.001), and were more obese (35.1% of individuals with BMI ≥40 vs 15.1%, p<0.001). After propensity score weighting, standardised mean differences between groups were <0.1 for all covariates, showing adequate balance between groups at baseline after adjustment. In the main per-protocol analyses we found no evidence that GLP-1RA increased the incidence of SIS (HR 1.04; 95% CI 0.35, 3.14). Intention-to-treat analyses resulted in an HR of 1.36 (95% CI 0.51, 3.61). In analyses excluding individuals with no BMI information and using imputation for BMI missing values, respective HRs were 0.89 (95% CI 0.26, 3.14) and 1.29 (95% CI 0.42, 3.92). Stratified analyses showed no differences between subgroups. CONCLUSIONS/INTERPRETATION: Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity; however, the rarity of SIS events and the wide uncertainty of effect size (although null, effect may be compatible with a risk as high as threefold) calls for a cautious interpretation of our results. Further studies, including final evaluations from regulatory bodies, are called for to discard a causal link between GLP-1RA and suicidality.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hurtado I, Robles C, Peiró S, et al. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia. 2024. PMID: 39103719. doi:10.1007/s00125-024-06243-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。